Higher doses generally produce greater weight reduction, though some patients achieve excellent results on moderate doses
JamesSJCutlerPMelnykSJerniganSJanakLGaylorDWet al
At this point Ill just remind you (as we talked about in Part 1) that Novo Nordisk and the academic steering committee (with physicians who took over $7 million combined in payments from Novo Nordisk) designed the study so the question is whether or not they are poring over previous data they gathered on Semaglutide in other trials and trying to get a sample who would have the largest effect (for example, that cis white women would show the most, at least temporary, weight loss and cis white men would show the greatest cardiovascular reduction,) because it doesnt seem that these seriously gender-skewed samples can be explained by differences of incidence of being higher-weight and or existing CVD in cis-men and cis-women, nor does it seem like anyone would (let alone should!) go to the trouble of running a trial on every continent but Antarctica and still end up with almost 85% white people

Increasing the endogenous production of GLP-1 through increasing the L-cells may be an effective therapeutic approach to managing T2DM
Glutathione synthetase deficiency must be distinguished from other disorders presenting as hemolytic anemia with metabolic acidosis, unexplained organic acidemia, or in older individuals with chronic progressive neurologic problems and chronic metabolic acidosis